Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.67 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2906731 | 0.99 | HRH3 (0.66) | HRH3HRH1MEN1KMT2AESR2 | |
| SCHEMBL1422794 | 0.92 | HRH3 (0.67) | HRH3HRH1MEN1KMT2AESR2 | |
| SCHEMBL1422936 | 0.91 | HRH3 (0.66) | HRH3HRH1MEN1KMT2AESR2 | |
| SCHEMBL2907958 | 0.90 | HRH3 (0.55) | HRH3ESR2ESR1 | |
| SCHEMBL2913003 | 0.90 | HRH3 (0.55) | HRH3SLC2A1 | |
| SCHEMBL2907126 | 0.89 | HRH3 (0.53) | HRH3MEN1KMT2AESR2ESR1 | |
| SCHEMBL2913116 | 0.89 | HRH3 (0.53) | HRH3MEN1KMT2A | |
| SCHEMBL2913170 | 0.89 | HRH3 (0.53) | HRH3MEN1KMT2AESR2ESR1 | |
| SCHEMBL2914096 | 0.89 | HRH3 (0.53) | HRH3SLC2A1 | |
| SCHEMBL2913157 | 0.88 | HRH3 (0.52) | HRH3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102215-B1 | 4,5,6,7-TETRAHYDRO-THIENO [2,3-C]PYRIDINES AS H3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-09-01 | — | — | EP | claimed |
| US-20080146559-A1 | 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | US | claimed |
| EP-2102215-B1 | 4,5,6,7-TETRAHYDRO-THIENO [2,3-C]PYRIDINES AS H3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-20080146559-A1 | 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146559-A1 | 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives | HRH4, HRH3, HRH2 | HRH3 2/4885HRH1 4/4885MEN1 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.